论文部分内容阅读
2009年,我国启动了新一轮医药体制改革。如今六年多的时间过去了,伴随着“十二五”规划的收官,改革进入深水区。那么新医改启动至今得失几何?未来将走向何方?前不久,十二届全国人大常委会第十八次会议听取并审议了《国务院关于深化医药卫生体制改革工作进展情况的报告》,检验改革成效。国务院医改领导小组副组长、国家卫计委主任李斌,受国务院委托,向常委会作了报告。据李斌介绍,“十二五”以来,
In 2009, China launched a new round of pharmaceutical system reform. Now more than six years have passed, accompanied by the “Twelfth Five-Year Plan” ending, the reform into the Sham Shui Po. Not long ago, the Eighteenth Meeting of the Standing Committee of the 12th National People’s Congress listened to and considered the “Report of the State Council on Deepening the Progress of the Medical and Health System Reform,” to test the effectiveness of the reform . Li Bin, deputy director of the medical reform leading group under the State Council and director of the State Health Planning Commission commissioned by the State Council, made a report to the Standing Committee. According to Li Bin introduction, “Twelve-Five ”,